ASH 2018: Dr. Tait Shanafelt on the ECOG-ACRIN Cancer Research Group trial comparing FCR and Ibrutinib/Rituximab in Treatment Naïve CLL (chronic lymphocytic leukemia) of younger patients.

You are here:
Social media & sharing icons powered by UltimatelySocial